- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05848232
Single-Arm Study Evaluating Use of the CORA Catheters for the Crossing of Coronary Chronic Total Occlusions (Cora CTO)
A Prospective Single-Arm Multicenter Study Evaluating Use of the CORA Catheters for the Crossing of Coronary Chronic Total Occlusions
The goal of this clinical trial is to evaluate the safety and effectiveness of the coraFlex, coraForce, and coraCross catheters for crossing chronic total occlusions of the coronary arteries. The study will compare the rate of procedure success to success rates from previous trials.
Participants will undergo percutaneous coronary intervention (PCI) for a chronic total occlusion and be followed for 30 days post-procedure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Sara Finton
- Phone Number: 616-633-9178
- Email: sfinton@reflowmedical.com
Study Contact Backup
- Name: Vicky Joshi
- Email: vjoshi@reflowmedical.com
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
Contact:
- Lorenzo Azzalini, MD
- Phone Number: 206-685-9955
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Pre-Procedure Inclusion Criteria:
- Subject willing and able to provide informed consent and able to comply with the study protocol and follow up.
- Male or non-pregnant female ≥18 years of age at time of consent.
- Subjects experiencing clinical symptoms suggestive of ischemic heart disease or has evidence of myocardial ischemia attributed to the CTO target vessel and is scheduled for clinically indicated percutaneous revascularization.
- Subject is a candidate for PTCA, stenting, and emergency CABG.
Angiographic Inclusion Criteria:
- A minimum of one de novo or restenotic lesion with at least one target segment in a native coronary vessel meeting CTO criteria {defined as TIMI grade 0 flow} and estimated to be > 3 months duration by clinical history and/or comparison with a prior angiogram or electrocardiogram.
Exclusion Criteria:
Pre-procedure Exclusion Criteria:
- Subject unwilling or unable to comply with the protocol or follow-up requirements, in the opinion of the investigator.
- Subject life expectancy less than one year, in the opinion of the investigator.
- Subject is pregnant or planning to become pregnant during the course of the trial.
- Evidence of MI within 72 hours prior to the index procedure.
- History of stroke or transient ischemic attack within 6 months prior to the index procedure.
- Prior coronary interventional procedure (including coronary artery bypass graft surgery) of any kind within 30 days of the index procedure.
- Inability to tolerate DAPT with aspirin plus a P2Y12 inhibitor.
- Known allergies or sensitivities to heparin, antiplatelet drugs, or other anticoagulant therapies, which could not be substituted, including history of major bleeding event in the last 6 months.
- Allergy or sensitivity to contrast media that cannot be adequately pre-treated prior to the index procedure.
Subjects with known history of clinically significant abnormal laboratory findings ≤30 days prior to enrollment including:
- Neutropenia (<1000 neutrophils/mm3)
- Thrombocytopenia (<100,000 platelets/mm3)
- AST, ALT, ALP, or bilirubin > 1.5 times ULN
- Serum creatinine > 2.0 mg/dL
- Subject has signs/symptoms of systemic infection/sepsis (temperature ≥ 38.00 Celsius and WBC ≥12,000 cells/µL). If subject has localized infection or infection is adequately treated and controlled, per investigator discretion, patient may be enrolled.
Evidence of current clinical instability including:
- Sustained systolic blood pressure <100 mmHg or cardiogenic shock
- Acute pulmonary edema or severe congestive heart failure (NYHA class IV)
- Known or suspected acute myocarditis, pericarditis, endocarditis, or cardiac tamponade
- Known or suspected dissecting aortic aneurysm
- Hemodynamically significant valvular heart disease, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease.
- Requires mechanical circulatory support (e.g., Impella) during index procedure
- Subject is currently enrolled in another investigational device or drug trial that interferes with the study endpoints.
- Any concurrent, medical, psychological, or social condition which may significantly interfere with the subject's optimal participation in the study, in the opinion of the investigator.
Angiographic Exclusion Criteria:
- Target lesion is located within a stent that was placed < 9 months prior to the index procedure.
- Target vessel has other lesions proximal to the total occlusion with >75% stenosis (based on visual estimate) unless there is planned stenting of the proximal lesion as well.
- Angiography demonstrates extensive lesion related thrombus (TIMI thrombus grade 3 or 4).
- Fractured stents in the target vessel.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: coraFlex, coraForce, and/or coraCross Catheters
Single arm
|
The coraFlex catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
The coraForce catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
The coraCross catheter is intended to facilitate the intraluminal placement of conventional guidewires beyond occluded coronary lesions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure success defined as technical success and the absence of in-hospital Major Adverse Cardiovascular Events (MACE)
Time Frame: Through hospital discharge or 24 hours post-procedure (whichever comes first)
|
|
Through hospital discharge or 24 hours post-procedure (whichever comes first)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Lorenzo Azzalini, MD, University of Washington
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CP-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Occlusion
-
Assiut UniversityUnknownRight Coronary Artery OcclusionEgypt
-
North Texas Veterans Healthcare SystemTerminatedCoronary Stent OcclusionUnited States
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
-
Yonsei UniversityCompletedCoronary Artery OcclusionKorea, Republic of
-
Hamilton Health Sciences CorporationGlaxoSmithKlineUnknownCoronary Bypass Graft Failure/OcclusionCanada
-
Volgograd State Medical UniversityEnrolling by invitation
-
Universita di VeronaNational University of Ireland, Galway, IrelandRecruiting
-
University Hospital UlmRecruitingChronic Total Occlusion | Chronic Total Occlusion of Coronary ArteryGermany
-
Acibadem UniversityCompleted
-
Medical University of ViennaCompletedChronic Total Coronary Occlusion
Clinical Trials on coraFlex Catheter
-
University of British ColumbiaCompletedIschemia | Chronic Pain | Phantom Limb Pain | Vascular DiseaseCanada
-
University College Hospital GalwayCompleted
-
Coloplast A/SCompletedIntermittent Urethral CatheterizationDenmark
-
Coloplast A/SCompletedSpinal Cord InjuryDenmark
-
University Hospital, Basel, SwitzerlandBoston Scientific CorporationCompleted
-
Anhui Provincial HospitalCompletedBiliary CalculiChina
-
University of Massachusetts, WorcesterCompletedUrinary Retention | Bladder Dysfunction
-
Beijing Luhe HospitalCompletedMyocardial InfarctionChina
-
Charles University, Czech RepublicRecruitingAtrial FibrillationCzechia
-
HaEmek Medical Center, IsraelCompletedSingle Balloon Catheter Compared With Double Balloon Catheter for Ripening of the Unfavorable CervixInduction of LaborIsrael